This gene-based therapeutics stock could nearly triple, analysts say
Analysts initiated coverage of Scribe Therapeutics (SCTX), a gene-based therapeutics company that IPOed on Nasdaq in late July. Wells Fargo rated it overweight and set a $60 price target, implying 183% upside. Leerink set an outperform with a $37 target, and Guggenheim set a buy with a $50 target. Coverage cites its PCSK9 epigenetic silencing approach and expected first-in-human data in 1H 2027.
How this was made
The 30-second read
Why it matters
The article is primarily a sell-side initiation story with price targets and a stated future catalyst (first-in-human data in 1H 2027), which can influence near-term positioning but does not add new clinical results today.
Market read
Analyst initiation with large upside targets can drive short-term momentum, but the article’s only forward-looking fundamental catalyst is 1H 2027 first-in-human data.
What to watch
Key risk is execution and timing of the first-in-human data referenced for 1H 2027; dilution/financing risk post-IPO is not addressed in the text.
Background
Scribe Therapeutics IPOed in late July on Nasdaq and has surged more than 44% since debut, per the article.
Ticker impact
CNBC says three firms initiated coverage of Scribe Therapeutics, including Wells Fargo’s $60 target implying 183% upside and a 2027 first-in-human catalyst.
Near-term upside bias versus peers as PTs and OW/Outperform ratings circulate; follow-through likely depends on upcoming clinical milestones rather than the PT math alone.
The only concrete, time-relevant items in the text are the initiation ratings/price targets and the stated expectation for first-in-human data in 1H 2027.
Market effects
Reinforces investor appetite for gene-based therapeutics and epigenetic silencing platforms, potentially lifting sentiment for adjacent gene-editing names.
Limited, primarily US small/mid-cap biotech sentiment via analyst coverage.
Low; no cross-border regulatory or trial-readout details beyond the company’s pipeline framing.
Counterpoint
Large upside targets may be driven by optimistic assumptions; without new clinical data in the article, the move could fade if expectations outrun evidence.
Key entities
- companyScribe Therapeutics
Gene-based therapeutics company whose stock is the subject of analyst initiation coverage and PTs.
- analyst_firmWells Fargo
Initiated coverage with an overweight rating and a $60 price target.
- analyst_firmLeerink Partners
Initiated coverage with an outperform rating and a $37 price target.
- analyst_firmGuggenheim
Initiated coverage with a buy rating and a $50 price target.
